SK Plasma to Mass Produce "Liquid Gold" Medicines in Indonesia by 2026

A major new drug factory in Indonesia is set to begin production in 2026. The facility will manufacture vital medicines derived from human blood plasma. South Korean biotech firm SK Plasma is building the plant. It represents a significant investment in Southeast Asia's healthcare infrastructure. The factory will produce two key types of plasma-derived drugs. The first is immunoglobulin. These are antibody proteins that help fight infections. Patients with weakened immune systems rely on them. The second is albumin, a protein that regulates blood volume. It is critical for treating shock, burns, and liver disease. These medicines are often called "liquid gold" due to their high value and life-saving nature. Currently, many countries in the region depend heavily on imports. The new factory aims to improve drug security in Indonesia and neighboring nations. Local production can help ensure a more stable supply. It may also reduce costs and wait times for these essential treatments. SK Plasma's project is part of a larger global trend. Pharmaceutical companies are expanding plasma treatment production to meet rising demand. The Indonesia plant will be a key supplier for the entire Asia-Pacific region once operational.